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ALI = acute lung injury; ARDS = acute respiratory distress syndrome; [Atot] = total concentration of weak acids; [H+] = H+ concentration; PCO2 =
partial CO2 tension; [SID] = strong ion difference; THAM = tris-hydroxymethyl aminomethane.
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Introduction
Acidemia occurs commonly in critically ill patients. Certain
acidoses have specific remedies, for example insulin for the
patient with diabetic ketoacidosis, or fomepizole for the treat-
ment of methanol intoxication. However, the optimal manage-
ment of other forms of acidosis, such as lactic acidosis from
sepsis, is controversial. Specifically, it is unclear for many of
these disorders whether it is appropriate to attempt to correct
arterial pH through the administration of sodium bicarbonate or
other ‘buffering’ agents, while efforts to treat the underlying
cause of the acidosis proceed apace. Similarly, whether pH
should be corrected in patients with hypercapnea as a result of
lung protective strategies of mechanical ventilation is unknown.
Herein we describe the properties of several buffering agents
and review the evidence for their clinical efficacy. We do not
discuss the administration of sodium bicarbonate to patients
with bicarbonate-losing metabolic acidoses such as occurs with
diarrhea or renal tubular acidosis – a practice that enjoys
widespread acceptance. Similarly, the role of buffering agents in
treating intoxication is beyond the scope of the present review.
What is the harm associated with low pH?
Because we understand poorly both the effects of an
elevated arterial H+ concentration ([H+]) as well as the effects
of attempting to correct it, deciding whether to administer a
buffering agent such as sodium bicarbonate to patients with
non-bicarbonate-losing forms of metabolic acidosis is
difficult. Proponents of such an approach typically argue
along the following lines [1].
• An elevated arterial [H+], in and of itself, is harmful.
• The administration of buffer X intravenously will lower the
arterial [H+].
• Lowering the [H+] with buffer X confers clinical benefit.
• Any adverse effects of buffer X will be outweighed by its
benefit.
We first consider the evidence supporting the first assertion.
The remaining ones are discussed below in the context of
each individual agent.
What are the effects of an elevated [H+]?
Because protein function is sensitive to the [H+] of its
environment, an increase in arterial [H+] might be expected to
have important detrimental effects on a host of bodily
functions. However, it is unclear to what extent the arterial
blood pH reflects the intracellular pH, which seems likely to
be more relevant. By way of example, consider the effect of
decreasing blood flow to a tissue by 50%. According to the
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Abstract
The recognition and management of acid–base disorders is a commonplace activity for intensivists.
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Fick relationship the arterial–venous partial CO2 tension
(PCO2) difference will double, assuming that local CO2
production is constant. This will have the effect of raising the
tissue PCO2 and lowering its pH; however, the arterial PCO2
and pH are unchanged and hence do not reveal the
abnormality. The meaning of an individual arterial blood pH is
further limited when one considers the diversity of micro-
circulations and tissue metabolisms throughout the body. The
effects of the elevated [H+] may also be difficult to separate
from the effects of the accompanying anion; lactate buffered
to a pH of 7.4, for example, causes a decrease in cardiac
contractility in animal models [2]. Finally, discerning the effect
of an elevated [H+] from that of the underlying process
causing the acidosis – hypoperfusion, sepsis, or diabetic
ketoacidosis for example – is difficult.
Nevertheless, lowering the arterial pH has rather convincingly
been shown to cause a decrease in cardiac contractility. This
effect has been demonstrated in isolated [3,4] and whole
animal heart preparations [5,6], as well as in excised human
ventricular muscle [7]. The net influence of acidosis on the
cardiovascular system is complicated, however, by
concomitant stimulation of the sympathetic–adrenal axis. As a
result, acidemia has been shown to increase cardiac output
and pulmonary artery pressure, whereas pulmonary vascular
resistance is not changed [8]. The responsiveness of adre-
nergic receptors to circulating catecholamines is decreased
[9–11], and the load tolerance of the right ventricle is reduced
[12]. It is unclear whether resuscitability from induced
ventricular fibrillation is impaired [13–15]. Fewer patients with
an arterial pH below 7.1 have been studied, making it difficult
to draw any conclusions. Both respiratory and metabolic
acidoses appear to have similar effects, although the effects of
respiratory acidosis are more rapid, presumably because of
rapid diffusion of CO2 across cell membranes.
Acute hypercapnea causes a decrease in diaphragmatic
contractility and endurance time [16], along with an increase in
cerebral blood flow. In fact, acute elevation in PCO2 to more
than 70 mmHg may cause loss of consciousness and seizures
[17]. In contrast, more gradual elevations in PCO2 are well
tolerated, as exhibited by patients with chronic obstructive
pulmonary disease. Broad clinical experience with the
application of lung protective strategies of mechanical
ventilation in patients with acute lung injury (ALI) and status
asthmaticus suggests that modest acidemia (typically pH
7.15–7.30, PCO2 50–70 mmHg) is remarkably well tolerated. In
general, patients with so-called permissive hypercapnea have a
decrease in systemic vascular resistance, an increase in heart
rate, cardiac output, oxygen delivery, mean pulmonary artery
pressure, and mixed venous oxygen saturation, and unchanged
mean arterial pressure and pulmonary vascular resistance.
The effects of acidosis may differ according to type and
magnitude. Disparate effects of three types of extracellular
acidosis – inorganic, respiratory, and lactic – on left ventricular
function in isolated rabbit hearts have been described [18].
Lactic acidosis caused a significant increase in the time to
peak left ventricular pressure while retarding ventricular
relaxation, reinforcing the concept that lactate ions have an
independent effect on myocardial function. Different types
and severity of acidosis may also induce different patterns of
inflammatory response. For example, murine macrophage-like
cells stimulated with lipopolysaccharide exhibited an
essentially proinflammatory response when the media
contained hydrochloric acid, but an anti-inflammatory
response when the media contained lactic acid [19].
Furthermore, hydrochloric acid infusion decreased the blood
pressure in septic rats in a dose dependent manner, but
whereas rats with moderately severe acidosis (standard base
excess of 5–10 mEq/l) had increased plasma nitrate/nitrite
levels, rats with severe acidosis did not [20].
Are there beneficial effects to an elevation in [H+] in
critical illness?
Interesting data are emerging regarding potential protective
effects of acidosis, particularly hypercapnic acidosis, in various
experimental models. Acidosis has been shown to protect
cells in a variety of organs (heart, lung, brain, and liver)
against injury from a number of insults, including hypoxia
[21–25]. In contrast, hypocapnic alkalosis worsened
ischemia–reperfusion ALI in isolated rabbit lungs [26],
whereas hypercapnic and metabolic acidosis afforded
protection [27]. Buffering the hypercapnic acidosis attenuated
the protection conferred. Similarly, rabbits ventilated with
injurious tidal volumes exhibited less ALI histologically when
hypercapnea was present [28]. A protective effect of
hypercapnea on the development of ALI has also been
demonstrated for an experimental model of extrapulmonary
ALI in which rats were subjected to splanchnic ischemia–
reperfusion injury [29]. Hypercapnic acidosis was effective at
attenuating endotoxin-induced ALI in an in vivo rat model
[30]; in fact, both prophylactic and therapeutic hypercapnic
acidosis ameliorated lung injury. Conceivably, reducing cells’
mechanical work (e.g. in cardiac cells) and metabolic demand
during hypoxia may protect them from ischemia.
Interestingly, the ARDS Network trial [31], which
demonstrated reduced mortality in ALI and acute respiratory
distress syndrome (ARDS) using a protocol employing low
tidal ventilation, allowed for sodium bicarbonate infusion for
acidemia. Whether this therapy had any effect, either negative
or positive, on patient outcome is unclear.
In summary, the negative impact of an elevated arterial [H+] is
frequently difficult to discern. We consider the evidence for
and against the administration of different buffering agents
within the context of each agent below.
Buffering agents
Buffers have conventionally been defined in acid–base
chemistry as substances that allow a solution to ‘resist’261
changes in pH in response to administration of H+. Problems
exist with this definition, however. First, as discussed below,
conventionally defined buffers such as NaHCO3
– may cause
an increase in arterial [H+] in certain circumstances when
they are administered intravenously, while Stewart [32]
demonstrated that a solution containing weak acids (buffers)
– such as blood containing albumin – ‘resists’ changes in
[H+] much less effectively than the same solution without any
weak acid. Also, the use of the term ‘buffer’ obscures the
unique mechanisms of each agent. Neverthess, because of
its widespread use, we employ the term buffer to refer to any
agent whose intent is to raise the arterial pH when given
intravenously.
Sodium bicarbonate
Does sodium bicarbonate lower the arterial [H+]?
The effects of sodium bicarbonate infusion can be
understood within the following context. Although the
Henderson equation ([H+] = 24 × PCO2/[HCO3
–]) accurately
describes the dissociation equilibrium for carbonic acid, it is
misleading to assume that [HCO3
–] is an independent
determinant of [H+]. In fact, the independent determinants of
[H+] in the blood are the strong ion difference [SID], the total
concentration of weak acids [Atot], and the PCO2 [32]. Weak
acids [Atot] include substances such as albumin and PO4
–,
change relatively little acutely, and have little impact on [H+].
Strong ions are those that dissociate fully (or nearly so) in
aqueous solutions, such as Na+ and Cl–. Because they are
fully dissociated, strong ions do not participate in chemical
reactions in blood like weak ions (such as H+ or HCO3
–) do.
Because they do not react chemically, all that matters (for
acid–base purposes) is the net difference in their charges.
The [SID] is defined as the difference between the sum of the
major cations (Na+, K+, Ca2+, Mg2+) and the sum of the major
anions (Cl–, SO4
–, lactate) in the blood. [SID] is so important
because the difference in charges affects how much water
will dissociate into the charged species H+ and OH– (i.e.
[SID] is the major determinant of pH).
The arterial [HCO3
–] and pH depend simply and quite
inextricably on the [SID], [Atot], and PCO2. The intravenous
infusion of sodium bicarbonate solution typically lowers
arterial [H+] (raising the pH) through an increase in [SID].
This occurs because Na+ is a strong cation whereas HCO3
–
is not, but rather reacts with [H+] to create CO2. When
ventilation is not limited, the excess CO2 that is produced can
be eliminated, and arterial pH is increased so that most
[5,33–36], but not all [37,38], whole animal studies have
shown an increase in arterial pH when sodium bicarbonate is
administered. Additionally, two prospective, randomized
controlled trials conducted in mechanically ventilated patients
with lactic acidosis [39,40] demonstrated that sodium
bicarbonate given intravenously causes a modest increase in
arterial pH. When ventilation is fixed, however, as commonly
occurs in mechanically ventilated patients, the effect of
sodium bicarbonate may be to lower arterial pH, as was seen
in patients ventilated with a lung protective strategy [41].
However, evidence supporting an increase in arterial pH with
bicarbonate infusion does not alone support its use for the
treatment of acidosis. First, bicarbonate infusion has been
shown to stimulate the production of lactate in animal models
of hypoxic lactic acidosis [34,38], phenformin-induced lactic
acidosis [37], hemorrhagic shock [35], and diabetic keto-
acidosis [36,42]. As mentioned above, lactate is itself a strong
anion, which may have independent negative effects on
cardiac contractility [2]. Furthermore, the effects of bicarbonate
administration on intracellular pH are far from clear. Because
CO2 diffuses readily across cell membranes, sodium bicar-
bonate administration may cause a decrease in intracellular
pH. In fact, the findings of cellular and whole animal model
studies examining the effects of bicarbonate infusion on
intracellular pH are variable, with intracellular [H+] rising [36],
falling [37,38,43–48], not changing [4,14,34,35], or either
rising or falling depending on the buffer used [49,50]. Two
studies of normal volunteers using very different experimental
designs have investigated the effect of bicarbonate on
intracellular pH using magnetic resonance spectroscopy. In
one study [51] bicarbonate attenuated the decrease in
intracellular muscle pH during exercise induced metabolic
acidosis while raising the arterial pH and PCO2. In the other
study [46] sodium bicarbonate caused a fall in brain pH.
The effect of bicarbonate on intracellular pH may depend on
the extracellular nonbicarbonate buffering capacity [52]. In
this model, bicarbonate reacts with H+ to form H2O and CO2
(reaction 1). The abrupt decrease in [H+] caused by reaction
1 causes the dissociation of [H+] from nonbicarbonate buffer
(back titration of the buffer), which in turn reacts with
bicarbonate to produce more CO2. Finally, the CO2 diffuses
readily into cells, decreasing intracellular pH (an effect that
may be minimized by intracellular bicarbonate buffer).
Does sodium bicarbonate confer any beneficial effects?
In general, whole animal studies fail to demonstrate any
hemodynamic benefit of sodium bicarbonate therapy over
isotonic saline [5,33,34,37,38,53,54]. Additionally, two
randomized controlled trials of sodium bicarbonate therapy in
patients with lactic acidosis [39,40] found no benefit from this
therapy over sodium chloride in improving global hemodynamics
or the cardiovascular response to infused catecholamines.
The effects of sodium bicarbonate therapy in patients with
permissive hypercapnea have received little study,
notwithstanding the inclusion of sodium bicarbonate in the
aforementioned ARDS Network low tidal volume protocol
[31]. One small, uncontrolled study of patients receiving lung
protective ventilation for ALI showed a decrease in arterial pH
with bicarbonate therapy [41]. No benefit from sodium
bicarbonate has been found in the management of diabetic
ketoacidosis [55,56].
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Summary
Intravenous sodium bicarbonate may decrease the arterial
[H+] when ventilation is not limited, but its effect on intra-
cellular pH is unclear. Perhaps more importantly, no clinical
benefit from sodium bicarbonate has been demonstrated in
the setting of lactic or ketoacidosis, but volume overload,
hyperosmolarity [57], and a decrease in ionized calcium [40]
are known to complicate its use.
Carbicarb
Carbicarb is an equimolar mixture of sodium bicarbonate and
sodium carbonate that is not currently available clinically.
Carbicarb raises the [SID] (lowering the arterial [H+]) far
more [33,34,43,58] and boosts the PCO2 far less [33,34,45]
than does sodium bicarbonate when given intravenously to
animals with metabolic acidosis. If the inability of sodium
bicarbonate to demonstrate a benefit in patients with non-
bicarbonate-wasting forms of metabolic acidosis is due to
increased CO2 generation, then carbicarb should be a
superior agent. In fact, although carbicarb more consistently
lowers intracellular [H+] [34,43,45], studies of its effects on
hemodynamics have yielded conflicting findings [4,33,34,43].
This agent deserves further study.
Tromethamine
Tris-hydroxymethyl aminomethane (THAM) is a weak alkali
(pK = 7.8) that reduces arterial [H+] without producing CO2.
Because it penetrates cells easily, it also reduces intracellular
[H+]. Protonated THAM is excreted by the kidneys.
Although THAM has been commercially available for some time
and has seen considerable use outside North America, there
are few studies of its efficacy. THAM incompletely buffered
metabolic acidosis but significantly improved contractility and
relaxation in an isolated blood perfused rabbit heart model [59].
The combination of THAM and sodium bicarbonate perfectly
buffered acidosis without modifying CO2, resulting in a
significant improvement in contractility. Weber and colleagues
[60] studied the effect of THAM on systemic hemodynamics in
12 patients with ARDS in whom permissive hypercapnea was
induced with a target CO2 of 80 mmHg. Hypercapnea had the
following effects on hemodynamics in control patients, in whom
no attempt was made to correct the pH: reduced systemic
vascular resistance, mean arterial pressure and myocardial
contractility, and increased cardiac output and pulmonary
artery pressure. Patients who received THAM experienced
significantly less myocardial depression when compared with
control patients, whereas the effects of hypercapnea on mean
arterial pressure and mean pulmonary artery pressure were
ameliorated. Administration of THAM to 10 patients with
acidosis and ALI caused significant improvements in arterial pH
and base deficit, as well as a decrease in CO2 that was not
adequately explained by the effects of ventilation [41].
Whether it is even desirable to ‘buffer’ hypercapnea in ALI
and hypoperfusion states is unclear, as discussed above.
THAM also has potentially serious side effects, including
hypoglycemia, hyperkalemia, extravasation related necrosis,
and, in neonates, hepatic necrosis [61]. Nevertheless, THAM
is an interesting agent that deserves further study, including
as a potential therapy for patients with lactic acidosis.
Alternative agents for lactic acidosis
Dichloroacetate
Conceivably, the lactic acidosis of sepsis may be due in part
to impaired pyruvate oxidation. The pyruvate dehydrogenase
complex is a key regulator of carbohydrate metabolism. This
complex is inactivated by a pyruvate dehydrogenase kinase
that may be activated by sepsis [62], leading to pyruvate
accumulation and subsequently an increase in lactate.
Dichloroacetate stimulates pyruvate kinase, increasing the
oxidation of pyruvate to acetyl coenzyme A.
Initial studies of dichloroacetate in animals and humans were
indeed promising, demonstrating that dichloroacetate
effectively reduced arterial [H+] and lactate levels [63–65].
There has been one large, randomized, placebo-controlled
trial of dichloroacetate in patients with lactic acidosis due to
sepsis, cardiogenic shock, or massive hemorrhage. Although
dichloroacetate reduced the arterial blood lactate
concentration and improved the arterial pH, it had no effect
on hemodynamics or survival [66]. Further studies of
dichloroacetate in other patient populations and using
different dosing schedules are warranted. Currently, this
therapy is investigational.
Thiamine
Patients with lactic acidosis due to thiamine deficiency (beri
beri) may respond promptly to its administration. Patients at
risk include those with chronic alcoholism, malignancy,
chronic illness, and short bowel syndrome. Lactic acidosis
may also develop in HIV infected patients receiving nucleo-
side analog reverse transcriptase inhibitors [67]. This
disorder is thought to represent drug induced mitochondrial
dysfunction, and there are anecdotal reports of improvement
with thiamine [68]. Although thiamine is an essential cofactor
for pyruvate dehydrogenase, its utility in sepsis with lactic
acidosis has not been studied.
Volume expanders and acid–base disorders
Considerable debate exists regarding the relative merits of
sodium chloride, lactated Ringer’s solution, or various colloid
solutions in the resuscitation of patients in shock. The
different chemical compositions of these fluids translate into
different acid–base consequences. For example, infusing
large volumes of normal saline intravenously lowers the [SID]
(because the [SID] of saline is zero), raising [H+] (and
lowering pH). Whether the ‘dilutional acidosis’ that results is
harmful, inconsequential, or even protective to the patient is
unclear. Lactated Ringer’s solution also has an [SID] of zero
but, because lactate is metabolized in the liver (assuming
adequate hepatic perfusion and function), the effect is similar
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to infusing a fluid with a positive [SID]. Whether this might be
advantageous is not known. New formulations of colloids have
been investigated; in an animal model of septic shock, volume
expansion with Hextend (Bio Time, Inc., Berkeley, CA, USA) –
a synthetic colloid in a balanced electrolyte solution that does
not produce metabolic acidosis in humans – conferred longer
survival when compared with 0.9% normal saline [69].
Conceivably, the differing effects of various volume
expanders on acid–base status may be important clinically,
but it is the authors’ view that considerably more work remains
to be done in this area before volume expanders other than
normal saline can be recommended. A detailed analysis of
this subject is beyond the scope of the present review.
When should I administer a buffering agent?
The lack of evidence supporting buffer therapy in human
acidosis makes it difficult to provide explicit recommendations.
Currently, it is unclear whether it is ever advantageous to
administer a buffering agent to a patient with lactic acidosis or
ketoacidosis. In fact, we do not recommend administration of
sodium bicarbonate to patients with lactic acidosis, regardless
of the pH. This includes lactic acidosis caused by
hypoperfusion, sepsis, mitochondrial dysfunction, or liver failure,
or in the setting of cardiopulmonary bypass. If the decision is
made to administer sodium bicarbonate, then slow infusion is
preferable and objective measures of benefit (or harm) should
be sought. Further study into the efficacy of alternative buffering
agents such as THAM and carbicarb is merited.
In patients with severe hyperchloremic metabolic acidosis from
diarrhea or renal tubular acidosis, the administration of sodium
bicarbonate is reasonable. Whether a patient will benefit from
this therapy is difficult to predict and probably depends on the
clinical circumstance. Patients with critical respiratory compro-
mise, who cannot easily compensate for acidemia, could also
benefit. Nevertheless, we find these patients to be quite rare. In
the much more common circumstance of modest hyper-
chloremic acidosis, attempting treatment with buffers is unlikely
to be helpful and may serve to distract the clinician from
addressing the underlying problem.
When buffer therapy is given its effect can be monitored by
serial determination of arterial blood pH, PCO2, and serum
anion gap corrected for albumin concentration. Failure to
correct for the nearly ubiquitous hypoalbuminemia present in
the critically ill introduces a systematic error in the detection
of unidentified anions such as lactate or ketoacids [70]. An
alternative approach is to calculate the strong ion gap, but
this requires measurement of albumin and phosphate
concentrations as well as a little more mathematics, and this
may be too cumbersome for regular clinical use.
Conclusion
Acidemia has both harmful and beneficial biological effects.
Sodium bicarbonate is generally ineffective in raising pH
when ventilation is limited, as in patients with ARDS. Even
when alkalinizing agents can correct the pH, evidence of
efficacy is lacking. Thus, these treatments should not be
considered standard therapy in patients with organic
acidoses, such as lactic acidosis. Rather, attention should be
directed toward correcting the underlying basis for the
acidosis. Alternative buffer agents, such as tromethamine,
offer potential advantages over sodium bicarbonate, but
clinical trials in humans are lacking.
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